Published in Oncotarget on October 13, 2015
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem (2009) 40.90
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res (2012) 15.84
Mitogen-activated protein kinase pathways. Curr Opin Cell Biol (1997) 9.10
The 2005 World Health Organization reevaluation of human and Mammalian toxic equivalency factors for dioxins and dioxin-like compounds. Toxicol Sci (2006) 6.86
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab (2008) 5.94
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev (2007) 5.21
Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist (2003) 3.04
Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. Toxicol Sci (2011) 2.48
Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res (2005) 2.23
PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase. Mol Pharmacol (1998) 2.16
The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem Pharmacol (2008) 1.90
An introduction to the molecular basics of aryl hydrocarbon receptor biology. Biol Chem (2010) 1.65
Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target. Toxicol Sci (2013) 1.53
Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer (2014) 1.46
Role of aryl hydrocarbon receptor in cancer. Biochim Biophys Acta (2013) 1.37
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res (2006) 1.27
Activation of mitogen-activated protein kinases (MAPKs) by aromatic hydrocarbons: role in the regulation of aryl hydrocarbon receptor (AHR) function. Biochem Pharmacol (2002) 1.17
Role of BRAF in thyroid oncogenesis. Clin Cancer Res (2011) 1.17
Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene (2002) 1.15
A-MADMAN: annotation-based microarray data meta-analysis tool. BMC Bioinformatics (2009) 1.12
Phosphorylation analysis of 90 kDa heat shock protein within the cytosolic arylhydrocarbon receptor complex. Biochemistry (2004) 1.09
Subcellular localization of the aryl hydrocarbon receptor is modulated by the immunophilin homolog hepatitis B virus X-associated protein 2. J Biol Chem (2000) 1.07
The aryl hydrocarbon receptor meets immunology: friend or foe? A little of both. Front Immunol (2014) 1.01
Dioxin induces transcription of fos and jun genes by Ah receptor-dependent and -independent pathways. Toxicol Appl Pharmacol (1996) 1.00
A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet (2013) 0.98
A critical role for MAP kinases in the control of Ah receptor complex activity. Toxicol Sci (2004) 0.98
The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways. Invest New Drugs (2014) 0.93
CYP1B1 expression in human lung. Drug Metab Dispos (2001) 0.92
Misidentification of putative medullary thyroid cancer cell lines RO-H85-1 and RO-D81-1. J Clin Endocrinol Metab (2013) 0.92
Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations. Thyroid (2014) 0.92
ERK kinase inhibition stabilizes the aryl hydrocarbon receptor: implications for transcriptional activation and protein degradation. J Biol Chem (2004) 0.88
A general method to derive robust organ-specific gene expression-based differentiation indices: application to thyroid cancer diagnostic. Oncogene (2012) 0.87
Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. Br J Cancer (2009) 0.86
Pharmacological inhibitors of JNK and ERK kinases SP600125 and U0126 are not appropriate tools for studies of drug metabolism because they activate aryl hydrocarbon receptor. Gen Physiol Biophys (2008) 0.86
Dietary flavonoids as cancer-preventive and therapeutic biofactors. Front Biosci (Schol Ed) (2011) 0.84
Role of mitogen-activated protein kinases in aryl hydrocarbon receptor signaling. Chem Biol Interact (2007) 0.84
Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse. Invest New Drugs (2006) 0.81
Peroxisome proliferator-activated receptor gamma in the human pituitary gland: expression and splicing pattern in adenomas versus normal pituitary. J Neuroendocrinol (2007) 0.80
Inhibition of the MEK-1/p42 MAP kinase reduces aryl hydrocarbon receptor-DNA interactions. Biochem Biophys Res Commun (2004) 0.79
The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells. J Neuroendocrinol (2011) 0.77
AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up. PLoS One (2014) 0.77
An integrative framework identifies alternative splicing events in colorectal cancer development. Mol Oncol (2013) 0.83
Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells. PLoS One (2015) 0.79
Human miRNome profiling in colorectal cancer and liver metastasis development. Genom Data (2014) 0.78
Loss of ZFP36 expression in colorectal cancer correlates to wnt/ ß-catenin activity and enhances epithelial-to-mesenchymal transition through upregulation of ZEB1, SOX9 and MACC1. Oncotarget (2016) 0.76
Clinical significance of circulating tumor cells and cell-free DNA in pediatric rhabdomyosarcoma. Mol Oncol (2022) 0.75
Clinical presentation and management of acromegaly in elderly patients. Hormones (Athens) (2020) 0.75